DHR · 10-Q · 2026Q3 · Full report

China Healthcare Policy Changes

DANAHER CORP /DE/ · 2026-10-21 · Importance 37 · Surprise 32

Danaher reported that China’s volume-based procurement program, reimbursement changes and related healthcare policy changes reduced Diagnostics pricing by 1.0% in the third quarter and 1.5% for the first nine months of 2026. The nine-month decline in Diagnostics core sales in China was partially attributable to the pricing impact of these policy changes. Management said the Company is moving beyond the most significant year-over-year effects that began in late 2024, and China core sales increased year over year in the third quarter. The policy changes remain relevant to pricing and demand across the Diagnostics segment.

Key facts

• Diagnostics price decreases of 1.0% in the three-month period and 1.5% in the nine-month period ended September 25, 2026 were primarily attributable to China’s volume-based procurement program and reimbursement changes, and sales promotions. source
• The core sales decrease in China in the nine-month period ended September 25, 2026 was partially attributable to the pricing impact of China’s healthcare policy changes. source